Influence of Vanadyl Sulphate [VOSO4] on Biochemical Activity and Morphology of Control and Streptozotocin-Diabetic Rat Liver Golgi Complexes

Polish Journal of Pathology

Volumn 55, Issue 1, 2004, Pages 25-32

  Da̧broś, Wojciech ^a   Goc, Anna ^b   Turyna, Bohdan ^b   Kordowiak, Anna M ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHLORIDE; STREPTOZOCIN; VANADIUM DERIVATIVE; VANADYL SULFATE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; GOLGI COMPLEX; LIVER; NONHUMAN; RAT; STREPTOZOCIN DIABETES;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GOLGI APPARATUS; LIVER; MICROSCOPY, ELECTRON; RATS; RATS, WISTAR; VANADIUM COMPOUNDS;

EID: 2342523127     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Aharon Y, Mevorach M, Shamoon H: Vanadyl sulphate does not enhance insulin action in patients with type 1 diabetes. Diabetes Care 1998, 21, 2194-2195.
2. Al-Altas OS, Al-Dagheri NM, Vigo NT: Vanadate enhances insulin-receptor binding in gestational diabetic human placenta. Cell Biochem Funct 1995, 13, 9-14.
3. Azay J, Bres J, Krogniak M, Teissedre PL, Cabanis JC, Serrano JJ Cros G: Vanadium pharmacokinetics and oral bioavailability upon single-dose administration of vanadyl sulphate to rats. Blackwell Sci Fund Clin Pharmacol 2001, 15, 313-324.
4. Badmaev V, Prakash S, Majeed M: Vanadium: A review of its potential role in the fight against diabetes. J Alternat Complement Med 1999, 5, 273-291.
5. Bhanot S, Girn J, Poucheret P, McNeill JH: Effects of bis(maltolato)oxovanadium(IV) on protein serine kinases in skeletal muscle of streptozotocin-diabetic rats Mol Cell Biochem 1999, 202, 131-140.
6. Cam MC, Brownsey RW, McNeill JH: Mechanism of vanadium action: insulin-mimetic or insulin enhancing agent. Can J Physiol Pharmacol 2000, 78, 829-847.
7. Cam MC, Li WM, McNeill JH: Partial preservation of pancreatic B-cells by vanadium: evidence for long-term amelioration of diabetes. Metabolism 1997, 46, 769-778.
8. Cortizo AM, Etcheverry SB: Vanadium derivatives act as growth factor-mimetic compounds upon differentiation and proliferation of osteoblast-like UMR106 cells. Mol Cell Biochem 1995, 145, 97-102.
9. Da̧broś W, Dziga D, Gryboś R, Kordowiak AM: Biochemical and morphological alterations in rat liver Golgi complexes after treatment with bis(maltolato)oxovanadium(IV) [BMOV] or maltol alone. Pathol Res Pract 2000, 196, 561-568.
10. DeCremer K, VanHulle M, Cherry C, Cornelis R, Strijckmansk K, Dams R, Lameire N, Vanholder R: Fractionation of vanadium complexes in serum, packed cells and tissues of Wistar rats by means of gel filtration and anion-exchange chromatography. J Biol Inorg Chem 2002, 7, 884-890.
11. Domingo JL: Vanadium and tungsten derivatives as antidiabetic agents. A review of their toxic effects. Biol Trace Element Res 2002, 88, 97-112.
12. Fantus IG, Degaron G, Lai R, Tang S: Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling. Mol Cell Biochem 1995, 153, 103-112.
13. Fawcett JP, Farquhar SJ, Thou T, Shand BI: Oral vanadyl sulphate does not affect blood cells, viscosity or biochemistry in humans. Pharmacol Toxicol 1997, 80, 202-206.
14. Fleischer B: Isolation and characterisation of Golgi apparatus from rat liver. In: Methods in Enzymology. Fleischer S, Packer L, eds. Acad Press Inc New York 1974, Vol 31A, pp180-191.
15. Gearldes CFGC, Castro MMCA, Sherry AD, Ramasamy R: Influence of vanadate on glycolysis, intracellular sodium and pH in perfused rat hearts. Mol Cell Biochem 1997, 170, 53-64.
16. rd ed. Butterworths, London 1988, Vol 1, pp 329-412.
17. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, Jiang ZY, Willsky GR, Kahn CR: Metabolic effects of vanadyl sulphate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. Metabolism 2000, 49, 400-410.
18. Karnovsky MJ. A formaldehyde-glutaraldehyde fixative of high osmolarity for use in electron microscopy. J Cell Biol 1965, 27, 137A-138A.
19. Khendelwal RL, Pugazhenthi S: Vanadium as a potential therapeutic agent for the treatment of diabetes mellitus. In: Metal Ions in Biology and Medicine. Callery P, Corbella J, Domingo JL, Ethienne JC, Llobet JM, Libbey J, eds. Eurotext Paris 1996, Vol 4, pp 673-675.
20. Kordowiak AM, Da̧broś W, Kajda B: The influence of a new vanadium complex, bis(2,2′-biopyridine)oxovanadium(IV) sulphate on liver Golgi complexes from control and streptozotocin-diabetic rats. Horm Metab Res 2002, 34, 556-560.
21. Kordowiak AM, Nikiforuk A, Da̧broś W: Biochemical and morphological study on liver Golgi complex in streptozotocin-diabetic and control rats treated with bis(kojato)oxovanadium(IV) [VO(ka)2]×2H2O. Part I. One week treatment with vanadium compound. Pol J Pathol 2000, 51, 9-16.
22. Kordowiak AM, Trzos R, Gryboś R: Insulin-like effects on liver Golgi membrane preparations of bis(oxalato)oxovanadate(IV) complex ion, a new vanadate compound. Horm Metab Res 1997, 29, 104-108.
23. Levin SR, Aftergood DE, Fanous P, Whitson RH: Inhibition of insulin receptors by vanadium and ouabain. Life Sci 1998, 42, 1889-1896.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with Folin phenol reagent. J Biol Chem 1951, 193, 265-275.
25. McNeill JH, Battell M, Cam M, Dai S, Thompson K, Yuen VG: Oral vanadium and lowering of blood glucose. Diabetes 1994, 43, 1268.
26. Poucheret P, Verma S, Grynpas MD, McNeill JH: Vanadium and diabetes. Mol Cell Biochem 1998, 188, 73-80.
27. Rehder D, Pessoa JC, Geraldes CFGC, Castro MMCA, Kabanos T, Kiss T, Meier B, Micera G, Pettersson L, Rangel M, Salifoglou A, Turel I, Wang D: In vitro study of the insulin-mimetic behaviour of vanadium (IV, V) coordination compounds. J Biol Inorg Chem 2002, 7, 384-396.
28. Semiz S, McNeill JH: Oral treatment with vanadium of Zucker fatty rats activates muscle glycogen synthesis and insulin-stimulated protein phosphatases-1 activity. Mol Cell Biochem 2002, 236, 123-131.
29. Shafrir E, Spielman S, Nachliel I, Khamaisi M, Bar-On H, Ziv E: Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obeses gerbil. Diabetes Metab Res Rev 2001, 17, 55-66.
30. Somogyi MJ, Nelson N: Determination of reducing sugars and carbohydrates. In: Methods in Carbohydrate Chemistry. Whistler R, Wolprom R, eds. Acad Press Inc, New York, London 1962 Vol 1, pp 380-394.
31. Thompson KH, Leichter J, McNeill JH: Studies of vanadyl sulphate as a glucose-lowering agent in STZ-diabetic rats. Biochem Biophys Res Commun 1993, 197, 1549-1555.
32. Tsiani E, Fantus JG: Vanadium compounds. Biological actions and potential as pharmacological agents. Trends Endocrinol Metab 1997, 8, 51-58.
33. Venable JH, Coggeshall RA: Simplified lead citrate stain for use in electron microscopy. J Cell Biol 1965, 25, 407-408.
34. Woo LCY, Yuen VG, Thompson KH. Vanadyl-biquanide complexes as potential synergistic insulin mimics. J Inorg Biochem 1999, 76, 251-257.
35. Yuen VG, Caravan P, Gelmini L, Glover N, McNeill JH, Setyawati M, Zhou R, Orvig C: Glucose lowering properties of vanadium compounds. Comparison of coordination complexes with maltol or kojic acid as ligands. J Inorg Biochem 1997, 68, 109-116.
36. Yuen VG, Orvig C, McNeill JH: Comparison of the glucose-lowering properties of vanadyl sulphate and bis(maltolato)oxovanadium(IV) following acute and chronic administration. Can J Physiol Pharmacol 1995, 73, 55-64.
37. Yuen VG, Orvig C, Thompson KH, McNeill JH: Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxo-vanadium (IV). Can J Physiol Pharmacol 1993, 71, 270-276.